[{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine, \u201cHyleukin-7 (GX-I7), US clinical trial approval for COVID-19 treatment for mild patients\u201d","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Genexine"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"Inovio Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"INOVIO and IVI Partner with Seoul National University Hospital to Start Phase 1\/2 Clinical Trial of INOVIO's INO-4800 in South Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Seoul National University Hospital"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EuBiologics Gets an IND Approval for Phase I\/II Clinical Trial of 'EuCorVac-19' in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"EuBiologics"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Launches Human Clinical Trial of Potential COVID-19 Antiviral Antibody Treatment Following Positive Pre-Clinical Results","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives MHRA Approval to Initiate Phase I Trial of Potential COVID-19 Antiviral Antibody Treatment, CT-P59, in the UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Receives Korean MFDS Approval to Initiate Phase I Trial of COVID-19 Antiviral Antibody Treatment Candidate, CT-P59, in Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Celltrion Announces Positive Interim Results From Phase I Trial of CT-P59, an Anti-COVID-19 Monoclonal Antibody Treatment Candidate","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Celltrion"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"PharmaMar","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Boryung Pharmaceutical Announces Superior Results for Plitidepsin (Aplidin\u00ae) Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Boryung Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Daewoong Begins Phase 1 Trial of Niclosamide as COVID-19 Drug in Korea","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"South Korea Daewoong Pharma eyes Phase II trials of coronavirus drug, shares jump","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Daewoong Pharmaceutical"},{"orgOrder":0,"company":"ST Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ST Pharm Presents Phase 1 Clinical Trial Results of HIV Treatment Candidate at AIDS 2022","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"ST Pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
STP0404 also demonstrated consistent pharmacokinetics at various dose levels showing drug exposure increased less-proportionally with dose, and presented an elimination half-life can support once daily dosing regimen.
The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
When injecting a single dose of DWRX2003 to hamsters as part of animal testing, a strong antiviral effect of the drug by the third day was observed and viral genome was barely found by the fifth day.
Daewoong plans to enter phase 2/3 trial in multiple nations before this year ends, and aims to apply for conditional approval or emergency use of the drug upon phase 2 clinical trial results.
The Phase I clinical trial is designed to evaluate the safety, tolerability and pharmacokinetics of CT-P59 in healthy subjects. The results demonstrated no significant drug-related adverse events, and no adverse events from the maximum tolerated dose cohort.
Korean Ministry of Food and Drug Safety (MFDS) has approved the company’s Investigational New Drug (IND) application for a Phase I clinical trial of CT-P59, a COVID-19 antiviral antibody treatment candidate.
Celltrion plans to conduct further global Phase II/III trials in patients with mild and moderate COVID-19 and anticipates results from these pivotal studies by the end of the year.
Celltrion’s COVID-19 antiviral antibody treatment candidate has been proven to be effective in neutralising different kinds of coronavirus related strains including the mutated G-variant strain of SARS-CoV-2 (D614G variant).
This phase 1 clinical trial of Hyleukin-7 is a multicenter, double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of Hyleukin-7 in adult patients with mild COVID-19 infection.